Humana Inc vs Ryanair Holdings plc — how do they compare? Humana Inc trades at $437.41 (market cap $47.61B), while Ryanair Holdings plc trades at $54.61 (market cap $27.95B). The key difference: Humana Inc is the larger of the two by market cap, and Ryanair Holdings plc pays the higher dividend (1.6%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Ryanair Holdings plc for 72 Days on average.
| HUM | RYAAY | |
|---|---|---|
Market Cap | $47.61B | $27.95B |
Volume | 1,827,332 | 1,519,820 |
Sector | Health | Industrials |
52-Week High | $409.85 | $73.82 |
52-Week Low | $163.67 | $51.95 |
Typical Hold Time | 53 Days | 72 Days |
Enterprise Value | $54.97B | $25.00B |
Dividend Yield | 0.89% | 1.6% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
RYAAY trades at $56.00 with a slight 0.24% daily gain, showing mixed technical signals amid bearish moving averages but neutral oscillators. Fundamentally, the airline maintains strong profitability with 12.13% net margins and attractive valuation multiples (P/E 13.95, EV/EBITDA 6.22), though recent Q3 2026 earnings are pending against high expectations. Analyst sentiment leans bullish with 65% buy ratings, but news highlights fuel cost pressures and Boeing MAX 10 certification delays as near-term concerns.
The stock presents a value opportunity given low valuations and robust cash flow, but investors face headwinds from oil price volatility and operational challenges. Upside hinges on Q3 earnings beat and cost management, while downside risks include prolonged certification delays and weaker winter traffic. Institutional ownership trends and dividend stability ($0.44 upcoming) provide support, but macro uncertainties warrant caution.
Trailing returns across standard periods
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →